Aerovate Therapeutics, Inc.
AVTE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $96 | $68 | $0 |
| Gross Profit | $0 | -$96 | -$68 | -$15 |
| % Margin | – | – | – | – |
| R&D Expenses | $53,187 | $64,219 | $38,622 | $14,987 |
| G&A Expenses | $21,409 | $17,190 | $14,615 | $8,035 |
| SG&A Expenses | $21,409 | $17,190 | $14,615 | $8,035 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$79 | -$3 |
| Operating Expenses | $74,596 | $81,409 | $53,237 | $23,022 |
| Operating Income | -$74,596 | -$81,409 | -$53,237 | -$23,022 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5,023 | $5,944 | $1,751 | $62 |
| Pre-Tax Income | -$69,573 | -$75,465 | -$51,486 | -$22,960 |
| Tax Expense | $55 | $56 | $25 | $3 |
| Net Income | -$69,628 | -$75,521 | -$51,511 | -$22,963 |
| % Margin | – | – | – | – |
| EPS | -2.44 | -2.87 | -2.1 | -1.87 |
| % Growth | 15% | -36.7% | -12.3% | – |
| EPS Diluted | -2.44 | -2.87 | -2.1 | -1.87 |
| Weighted Avg Shares Out | 28,582 | 26,331 | 24,472 | 24,410 |
| Weighted Avg Shares Out Dil | 28,582 | 26,332 | 24,472 | 24,410 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5,042 | $5,945 | $1,830 | $65 |
| Interest Expense | $0 | $0 | $0 | $65 |
| Depreciation & Amortization | $282 | $96 | $68 | $15 |
| EBITDA | -$74,314 | -$81,313 | -$53,169 | -$23,007 |
| % Margin | – | – | – | – |